Your browser doesn't support javascript.
loading
Cutaneous immune-related adverse events: incidence rates, risk factors and association with extracutaneous toxicity - a prospective study of 189 patients treated with checkpoint inhibitors at a Spanish tertiary care hospital.
Juan-Carpena, Gloria; Martínez-Banaclocha, Natividad; Palazón-Cabanes, Juan Carlos; Niveiro-de Jaime, María; Betlloch-Mas, Isabel; Blanes-Martínez, Mar.
Afiliación
  • Juan-Carpena G; Department of Dermatology, Morales Meseguer University Hospital, Murcia, Spain.
  • Martínez-Banaclocha N; Toxirel Investigation Group, Alicante, Spain.
  • Palazón-Cabanes JC; Toxirel Investigation Group, Alicante, Spain.
  • Niveiro-de Jaime M; Department of Oncology, Dr. Balmis University General Hospital, Alicante, Spain.
  • Betlloch-Mas I; Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain.
  • Blanes-Martínez M; Department of Dermatology, 12 de Octubre University Hospital, Madrid, Spain.
Clin Exp Dermatol ; 49(9): 991-1001, 2024 Aug 22.
Article en En | MEDLINE | ID: mdl-38372424
ABSTRACT

BACKGROUND:

Clinicians are increasingly prescribing immune checkpoint inhibitors (ICIs) to treat cancer, but the real-world incidence, characteristics and risk factors of cutaneous immune-related adverse events (cirAEs) are unclear.

OBJECTIVES:

To determine the incidence, features and risk factors of cirAEs and to measure their possible association with extracutaneous toxicity.

METHODS:

We conducted a prospective observational study in a Spanish tertiary care hospital, including people who started an ICI between March 2020 and May 2022. We used a survival analysis and a log-rank test to obtain and compare incidence rates, and a multivariate Cox model to detect risk factors for cirAEs.

RESULTS:

We included 189 patients, 82 (43.4%) of whom presented cutaneous toxicity. The incidence of cirAEs was 75.0 per 100 person-years, with a 50.0% probability of the appearance of a cirAE at 10 months of follow-up. The most frequent cirAE category was inflammatory dermatoses, and the most frequent types were pruritus, eczema and maculopapular eruptions. ICI combination therapy, a family history of psoriasis and rheumatological and pulmonary immune-related adverse events increased the risk of cirAEs.

CONCLUSIONS:

We found a high incidence of cirAEs, and they occurred early in the follow-up period. Dermatologists should be involved in the management of cirAEs, especially in people with risk factors.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Erupciones por Medicamentos / Centros de Atención Terciaria / Inhibidores de Puntos de Control Inmunológico Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: Clin Exp Dermatol Año: 2024 Tipo del documento: Article País de afiliación: España Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Erupciones por Medicamentos / Centros de Atención Terciaria / Inhibidores de Puntos de Control Inmunológico Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: Clin Exp Dermatol Año: 2024 Tipo del documento: Article País de afiliación: España Pais de publicación: Reino Unido